|
注册号: Registration number: |
ChiCTR2500100152 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-03 10:27:10 |
|
注册时间: Date of Registration: |
2025-04-03 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
精神分裂症的功能能力评估:BJ-PERFECT VR版验证 |
|
Public title: |
Functional Capacity Evaluation in Schizophrenia: Beijing Performance-based Functional Ecological Test VR Version Validation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
精神分裂症的功能能力评估:BJ-PERFECT VR版验证研究 |
|
Scientific title: |
Functional Capacity Evaluation in Schizophrenia: Beijing Performance-based Functional Ecological Test VR Version Validation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘夏 |
研究负责人: |
石川 |
|
Applicant: |
Liu Xia |
Study leader: |
Shi Chuan |
|
申请注册联系人电话: Applicant telephone: |
+86 189 4107 3123 |
研究负责人电话:
Study leader's |
+86 136 1117 4272 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liuxiaqq4529@163.com |
研究负责人电子邮件: Study leader's E-mail: |
shichuan@bjmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区花园北路51号 |
研究负责人通讯地址: |
北京市海淀区花园北路51号 |
|
Applicant address: |
No. 51, Huayuan North Road, Haidian District, Beijing |
Study leader's address: |
No. 51, Huayuan North Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京大学第六医院 |
||
|
Applicant's institution: |
Peking University Sixth Hospital |
||
|
研究负责人所在单位: |
北京大学第六医院 |
||
|
Affiliation of the Leader: |
Peking University Sixth Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)伦审第(37)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学第六医院(精神卫生研究所)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee, Peking University Sixth Hospital (Institute of Mental Health) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-04 00:00:00 | ||
|
伦理委员会联系人: |
王雪芹 |
||
|
Contact Name of the ethic committee: |
Wang Xueqin |
||
|
伦理委员会联系地址: |
北京市海淀区花园北路 51 号 |
||
|
Contact Address of the ethic committee: |
No. 51, Huayuan North Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6272 3770 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京大学第六医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking University Sixth Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区花园北路51号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 51, Huayuan North Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
勃林格殷格翰(中国)投资有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Boehringer Ingelheim(China)Investment Co.,Ltd. |
||||||||||||||||||||||
|
研究疾病: |
精神分裂症 |
||||||||||||||||||||||
|
Target disease: |
Schizophrenia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
主要目的: 分析检验BJ-PERFECT VR工具在精神分裂症患者和健康对照者中的信度和效度;建立BJ-PERFECT VR工具在中国健康人群中的常模。 次要目的: 分析精神分裂症患者认知功能损害对疾病负担的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
Main purpose: Analysis examined the BJ-PERFECT VR tool in patients with schizophrenia and healthy controlsDegree and validity; Establish the norm of BJ-PERFECT VR tool in Chinese healthy population. Secondary Purpose:To analyze the effect of cognitive impairment on disease burden in patients with schizophrenia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
精神分裂症患者: 1.存在严重或不稳定的躯体疾病; 2.患有符合 DSM-5 诊断标准的其他精神疾病,包括精神发育迟滞等; 3.6 个月内接受过改良电抽搐(Modified Electric Convulsive Therapy,MECT)治疗; 4.患有严重视觉障碍或红绿色盲; 5.不能耐受 VR 工具的情况,如过度出汗、方向障碍、平衡感受损等其他类似运动病症状,癫痫发作、失去意识、抽搐、头晕、恶心、皮肤过敏等; 6.拒绝签署知情同意书。 健康对照组: 1.存在不稳定或严重的躯体疾病; 2.诊断为任何精神疾病(包括精神发育迟滞)或神经系统疾病; 3.患有严重视觉障碍或红绿色盲; 4.两系三代亲属中患有各种精神障碍或遗传性神经系统疾病。 5.不能耐受 VR 工具的情况,如过度出汗、方向障碍、平衡感受损等其他类似运动病症状,癫痫发作、失去意识、抽搐。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients with schizophrenia: 1. Presence of severe or unstable medical disease; 2. Have other psychiatric disorders that meet DSM-5 diagnostic criteria, including mental retardation, etc.; Modified Electric Convulsive Therapy (MECT) within 3.6 months; 4. Suffer from severe visual impairment or red-green color blindness; 5. Inability to tolerate VR tools, such as excessive sweating, disorientation, impaired balance and other similar motion sickness symptoms, seizures, loss of consciousness, convulsions, dizziness, nausea, skin allergies, etc.; 6. Refusal to sign informed consent. Healthy control group: 1. Presence of unstable or serious physical illness; 2. Diagnosis of any psychiatric illness (including mental retardation) or neurological disorder; 3. Severe visual impairment or red-green color blindness; 4. Relatives of two lineages and three generations with various mental disorders or hereditary neurological diseases. 5. Intolerance of VR tools, such as excessive sweating, disorientation, impaired balance and other similar motion sickness symptoms, seizures, loss of consciousness, convulsions. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-19 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
网站:ResMan(www.medresman.org) 日期:研究结果发表后的6个月内。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Website: ResMan(www.medresman.org) Date: Within 6 months of publication of the results of the study. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表;电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form,CRF; Electronic Data Capture, EDC. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |